Taltz ® (ixekizumab) injektion

För fullständig produktresumé för Taltz® se FASS.

Denna information är endast avsedd för sjukvårdspersonal verksam i Sverige och som svar på din fråga. Informationen nedan är på engelska

Taltz® ▼ (ixekizumab): Tillgänglighet av biomarkörer

Lilly har inte testat biomarkörer i kliniska fas 3-prövningar. Det finns inga kommersiella biomarkörstester tillgängliga.

Phase 2 clinical trials

A biomarker to predict future response to ixekizumab therapy was investigated in a single phase 2 study and has not been replicated. This experiment evaluated the correlation between baseline mRNA expression of TRGV and clinical response to ixekizumab in patients with chronic moderate-to-severe plaque psoriasis. 1

There are no current commercial assays that test for TRGV levels, and there are no standards that would define high levels of TRGV.1

Phase 3 clinical trials

Lilly has not tested biomarkers in phase 3 studies. 

References

1. Krueger JG., Suarez-Farinas M, Beselin A, et al. Baseline expression of T cell receptor gamma-V gene family is associated with high levels of response to ixekizumab treatment in psoriasis. J Invest Dermatol 2015; 135: S32-S32. http://www.jidonline.org/article/S0022-202X(15)60202-0/pdf

Glossary

Lilly = Eli Lilly and Company

TRGV =  T cell receptor gamma-V

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Datum fӧr senaste ӧversyn 2019 M03 04


Kontakta Medicinsk Information på Lilly

Kontakta oss på telefon

Kontorstid vardagar 9.00-17.00

Eller så kan du

Skriv din fråga till oss